Drug
SHR7390
SHR7390 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Terminated(1)
Other(2)
Detailed Status
unknown2
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
completed125%
terminated125%
unknown250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT04676607
terminatedphase_1
The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
NCT03182673
unknownphase_2
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
NCT04355858
unknownphase_1
Phase I Study of SHR7390 in Patients With Advanced Solid Tumors
NCT02968485
Clinical Trials (4)
Showing 4 of 4 trials
NCT04676607Phase 2
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT03182673Phase 1
The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
NCT04355858Phase 2
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
NCT02968485Phase 1
Phase I Study of SHR7390 in Patients With Advanced Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4